Abbott Laboratories (NYSE:ABT) Given New $125.00 Price Target at Sanford C. Bernstein

Abbott Laboratories (NYSE:ABT) had its price target decreased by equities research analysts at Sanford C. Bernstein from $154.00 to $125.00 in a report released on Friday,Benzinga reports. The firm currently has an “outperform” rating on the healthcare product maker’s stock. Sanford C. Bernstein’s target price would indicate a potential upside of 14.95% from the stock’s current price.

A number of other analysts also recently weighed in on ABT. William Blair upgraded Abbott Laboratories to a “strong-buy” rating in a research report on Thursday, November 20th. Piper Sandler cut their price target on Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating on the stock in a research note on Friday. Evercore ISI cut their target price on shares of Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating on the stock in a research report on Friday. The Goldman Sachs Group decreased their price target on shares of Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating for the company in a research report on Friday. Finally, Royal Bank Of Canada cut their price target on shares of Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating on the stock in a report on Friday. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $141.84.

Abbott Laboratories Stock Up 0.1%

Abbott Laboratories stock traded up $0.14 during mid-day trading on Friday, reaching $108.75. The company’s stock had a trading volume of 5,161,265 shares, compared to its average volume of 9,150,906. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.24 and a current ratio of 1.70. The business’s 50 day simple moving average is $125.23 and its 200 day simple moving average is $128.54. The company has a market capitalization of $189.10 billion, a price-to-earnings ratio of 13.64, a price-to-earnings-growth ratio of 2.00 and a beta of 0.72. Abbott Laboratories has a 12 month low of $105.78 and a 12 month high of $141.23.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.50. Abbott Laboratories had a net margin of 31.88% and a return on equity of 17.60%. The firm had revenue of $11.46 billion for the quarter, compared to analyst estimates of $11.80 billion. During the same period in the prior year, the firm posted $1.34 earnings per share. The company’s quarterly revenue was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, research analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current year.

Hedge Funds Weigh In On Abbott Laboratories

Institutional investors have recently added to or reduced their stakes in the business. Brighton Jones LLC boosted its stake in Abbott Laboratories by 10.1% during the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock worth $5,850,000 after acquiring an additional 4,755 shares in the last quarter. Sivia Capital Partners LLC boosted its position in shares of Abbott Laboratories by 3.5% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock worth $648,000 after purchasing an additional 162 shares in the last quarter. Signet Financial Management LLC grew its stake in shares of Abbott Laboratories by 6.5% in the 2nd quarter. Signet Financial Management LLC now owns 3,066 shares of the healthcare product maker’s stock valued at $417,000 after buying an additional 188 shares during the period. McAdam LLC raised its stake in Abbott Laboratories by 15.7% during the 2nd quarter. McAdam LLC now owns 2,780 shares of the healthcare product maker’s stock worth $378,000 after buying an additional 377 shares during the period. Finally, Register Financial Advisors LLC boosted its holdings in Abbott Laboratories by 49.5% in the second quarter. Register Financial Advisors LLC now owns 3,590 shares of the healthcare product maker’s stock worth $488,000 after acquiring an additional 1,188 shares in the last quarter. 75.18% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Several sell?side analysts kept constructive ratings and still see meaningful upside — Piper Sandler cut its price target to $135 but remains “overweight,” and BTIG trimmed its target to $140 while keeping a “buy” call, signaling continued analyst confidence despite the pullback. Benzinga
• Positive Sentiment: Med tech (devices) and Established Pharmaceuticals delivered strong growth (double?digit devices, mid?single to high single pharma), which management says helped offset weakness in other segments and supports the company’s multi?year growth thesis. Blockonomi
• Positive Sentiment: Market commentators view the pullback as a potential buying opportunity for long?term investors because Abbott remains a cash?generative Dividend King with capacity for buybacks and continued margin improvement. MarketBeat
• Neutral Sentiment: Adjusted EPS of $1.50 matched consensus, showing underlying earnings resilience even as revenues lagged; GAAP results included items that lowered headline net income. Press Release
• Neutral Sentiment: Company guidance: Q1 2026 adjusted EPS of $1.120–1.180 (below the ~1.20 consensus) and FY 2026 adjusted EPS of $5.55–5.80 (around consensus). Guidance tempered near?term expectations but keeps mid/longer?term growth intact. Press Release
• Negative Sentiment: Revenue missed Street estimates (~$11.46–11.5B reported vs. ~$11.8–11.9B expected); the Nutrition business declined sharply (near?9% year?over?year) and Diagnostics weakened (lower COVID testing and volatility), which triggered the market sell?off. Reuters Blockonomi
• Negative Sentiment: Unusual bearish positioning: intraday put option volume spiked sharply, indicating heavy hedging or speculative bearish bets that can amplify downward price moves. (Reported market activity)
• Negative Sentiment: Regulatory/legal overhang: documents show India regulators are scrutinizing supply of a codeine?based cough syrup tied to abuse investigations, introducing potential reputational and compliance risk. Reuters

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.